http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Kyong Joo Lee ),( Jae Hyun Kim ),( Hee Man Kim ),( Sang Kil Lee ),( Woo Jin Lee ),( Seun Ja Park ),( The Korean Society Of Gastrointestinal Cancer ) 대한내과학회 2014 대한내과학회 추계학술대회 Vol.2014 No.1
Background: Type 3 gastric neuroendocrine tumor (NET) is different from type 1 and type 2 gastric NET in view of management approach. The standard treatment of type 3 gastric NET is suggested as radical gastrectomy. Clinically endoscopic treatment has been tried. The aim of this study was to investigate clinicopathologic features of type 3 gastric NET according to the treatment modalities. Methods: The Korean Society of Gastrointestinal Cancer has been conducting the Korean Gastroenteropancreatic Neuroendocrine Tumor Registry from 2012. This is a retrospective registry database of gastroenteropancreatic neuroendocrine tumor collected from 16 hospitals between 2002 and 2012. From the Registry, gastric NET patients with normal serum gastrin level (<100 pg/mL) were selected for analysis. Results: A total of 20 patients from 327 patients with gastric NET were classifi ed as type 3 Gastric NET. The mean age was 55.5 ± 11.52 years. The mean tumor size was 1.08 ± 1.10 cm. According to the WHO 2010 classification, 14 (70%) patients had grade 1, and 5 (25%) patients had grade 2. Endoscopic treatment was performed in 13 (65%) patients, and surgery was performed in 6 (30%) patients. Endoscopic treatment group was younger than surgery group. T1 stage was more prevalent in endoscopic treatment group than in surgery group. After treatment, the median follow-up time was 10 months, during when there was no death related to NET, but there was one disease-progression in surgery group. Conclusions: Clinically, Type 3 gastric NET has been frequently managed by endoscopy. However, proper evidence for endoscopic management should be further evaluated.